Last reviewed · How we verify
ROP+L-Dopa
ROP+L-Dopa is a combination therapy that pairs ropinirole (a dopamine agonist) with levodopa to enhance dopaminergic signaling in the brain for Parkinson's disease management.
ROP+L-Dopa is a combination therapy that pairs ropinirole (a dopamine agonist) with levodopa to enhance dopaminergic signaling in the brain for Parkinson's disease management. Used for Parkinson's disease.
At a glance
| Generic name | ROP+L-Dopa |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Dopamine agonist + Levodopa combination |
| Target | Dopamine receptors (D2/D3); Dopamine pathway |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Ropinirole directly stimulates dopamine receptors (particularly D2/D3), while L-Dopa is converted to dopamine in the brain to replenish depleted dopamine levels. Together, they provide complementary dopaminergic effects to reduce motor symptoms of Parkinson's disease. This combination approach allows for lower individual doses while maintaining therapeutic efficacy.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Dyskinesia
- Hallucinations
- Orthostatic hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ROP+L-Dopa CI brief — competitive landscape report
- ROP+L-Dopa updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI